Four million people die from diabetes annually. Novo Nordisk, a global healthcare company, has a mission to change that. Although it has a presence in 170 countries, is already helping 28 million patients, and supplies half of the world’s insulin, the company still faces an enormous challenge: novel drug approaches are needed, and drug development is a long, expensive process. The GLIA (Global Information & Analysis) team at Novo Nordisk aim to help by providing the best information possible to researchers and product teams.
Using natural language processing (NLP) to extract information from real world data sources
The answers Novo Nordisk need are buried within a myriad of sources of unstructured real world data. These data sources include research papers, news reports, market information, patient use information, and more.
“Finding accurate information in an ever-growing ocean of information is becoming more important than ever,” explains Novo Nordisk senior information scientist Solmaz Gabery Adams.
Extensive research informs every step on the long path to delivering healthcare, from identifying needs and undertaking drug discovery to clinical trials and regulatory review before bringing new treatments to market. At every stage, Novo Nordisk researchers and managers must make crucial decisions, including which projects to advance and which projects to leave behind.